Haoyu Zeng

Key Laboratory Of Molecular Target & Clinical Pharmacology And State Key Laboratory Of Respiratory Disease
Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma.

Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma.

Journal: Cancer immunology, immunotherapy : CII

Published: March 06, 2026

Porphyromonas gingivalis promotes oral squamous cell carcinoma progression via the IL-6/EZH2/Snai2 axis.

Porphyromonas gingivalis promotes oral squamous cell carcinoma progression via the IL-6/EZH2/Snai2 axis.

Journal: Scientific reports

Published: October 27, 2025

MSCohi-O lenses attenuate corneal transplant rejection via HLA-G5 driven Treg cell expansion.

MSCohi-O lenses attenuate corneal transplant rejection via HLA-G5 driven Treg cell expansion.

Journal: BMC ophthalmology

Published: April 21, 2025

The validity of immunotherapy against palate mucoepidermoid carcinoma based on data enrichment from oral cancer database.

The validity of immunotherapy against palate mucoepidermoid carcinoma based on data enrichment from oral cancer database.

Journal: Gene

Published: March 27, 2025

TLR3-overexpressing umbilical cord mesenchymal stromal cells suppress immune responses to attenuate high-risk corneal transplantation rejection.

TLR3-overexpressing umbilical cord mesenchymal stromal cells suppress immune responses to attenuate high-risk corneal transplantation rejection.

Journal: Stem cell research & therapy

Published: January 25, 2025

Response to Yu et al.

Response to Yu et al.

Journal: Stem cell reports

Published: January 08, 2025

Targeting CD276: a promising strategy for CAR-NK cell immunotherapy in human oral tongue squamous cell carcinoma.

Targeting CD276: a promising strategy for CAR-NK cell immunotherapy in human oral tongue squamous cell carcinoma.

Journal: BMC cancer

Published: December 12, 2024

Promising approach for targeting ROBO1 with CAR NK cells to combat ovarian cancer primary tumor cells and organoids.

Promising approach for targeting ROBO1 with CAR NK cells to combat ovarian cancer primary tumor cells and organoids.

Journal: Future science OA

Published: July 29, 2024

C188-9 reduces patient-specific primary breast cancer cells proliferation at the low, clinic-relevant concentration.

C188-9 reduces patient-specific primary breast cancer cells proliferation at the low, clinic-relevant concentration.

Journal: Journal of translational medicine

Published: May 25, 2024

Efficacy of the induced pluripotent stem cell derived and engineered CD276-targeted CAR-NK cells against human esophageal squamous cell carcinoma.

Efficacy of the induced pluripotent stem cell derived and engineered CD276-targeted CAR-NK cells against human esophageal squamous cell carcinoma.

Journal: Frontiers in immunology

Published: November 13, 2023

Efficacy of MUC1-targeted CAR-NK cells against human tongue squamous cell carcinoma.

Efficacy of MUC1-targeted CAR-NK cells against human tongue squamous cell carcinoma.

Journal: Frontiers in immunology

Published: November 13, 2023

BME-free primary patient-specific organoids obtained with a one-day mimicking method to replicate the corresponding tumor for personalized treatment options.

BME-free primary patient-specific organoids obtained with a one-day mimicking method to replicate the corresponding tumor for personalized treatment options.

Journal: Frontiers in oncology

Published: July 07, 2023

Showing 1-12 of 16

Last Updated: 09/26/2026